Physician profile
Marcus Morra
NPI 1407926058
$1,775.08
in general payments reported to CMS, 2019-2025
30 companies · $56.58 in 2025
The $56.58 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.96 · 2021: $188 · 2022: $443 · 2023: $377 · 2024: $653 · 2025: $56.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.20 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $180.20 | 2023-2024 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $119.85 | 2023-2024 | Jelmyto |
| Accord Healthcare, INC. | $107.03 | 2023-2024 | |
| Pfizer INC. | $89.11 | 2019-2024 | |
| Astellas Pharma US INC | $87.30 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $86.31 | 2021-2024 | Provenge |
| Merck Sharp & Dohme LLC | $77.01 | 2021-2024 | Welireg, Keytruda, Lynparza |
| Antares Pharma, INC. | $73.70 | 2022-2024 | Xyosted |
| Myriad Genetic Laboratories, INC. | $73.59 | 2021-2023 | Prolaris |
| Blue Earth Diagnostics | $69.43 | 2021-2022 | |
| Myovant Sciences INC. | $68.22 | 2022 | |
| Tolmar, INC. | $58.84 | 2023-2024 | |
| Rochester Medical Corporation | $48.83 | 2021-2022 | |
| Janssen Biotech, INC. | $47.29 | 2021-2023 | Erleada |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $45.75 | 2023-2024 | Resonance, Ncircle |
| C. R. Bard, INC. & Subsidiaries | $37.68 | 2024-2025 | Purewick Female External Catheter |
| Urovant Sciences INC | $29.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.95 | 2023 | Lynparza |
| Ambu INC. | $24.71 | 2022 | |
| Coloplast Corp | $23.64 | 2023 | Porges Coloplast |
| Tempus Ai, INC | $22.93 | 2024 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $20.43 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $20.22 | 2022 | |
| Photocure INC | $19.61 | 2024 | Cysview |
| Vertex Pharmaceuticals Incorporated | $18.46 | 2024 | |
| Endo Pharmaceuticals INC. | $17.94 | 2024 | Aveed, Xiaflex |
| Boston Scientific Corporation | $16.85 | 2023 | Rezum Generator |
| Teleflex LLC | $15.63 | 2024 | Urolift |
| Axonics, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Morra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.